The biopharmaceutical company Omnix Medical, known for creating advanced anti-infectives to combat serious infections, has reported today that their upcoming Phase II trial for their innovative anti-infective, OMN6, has received approval from the FDA.

The latest clinical findings of Revumenib will be unveiled at the 2023 ASH Congress, demonstrating its potential effect and setting the stage for subsequent investigations.

The OCEANIC-AF phase III trial comparing asundexian and apixaban in stroke-risk atrial fibrillation patients will end early. This is based on the Independent Data Monitoring Committee's recommendation, as asundexian showed lower efficacy than the control. Bayer will analyze the data further and share the results later.

The LAG-3 molecule can negatively requlate T cells and plays an important role in maintaining thestability of the immune system and promoting tumor immune escape. As one of the new targets, LAG-3has great potential in tumor immunotherapy.

Vigil Neuroscience has revealed encouraging initial results from the Phase 2 IGNITE clinical trial. This trial aims to test the potential of Iluzanebart (VGL101) in treating ALSP.

On 11 Dec 2023, the latest clinical trial of Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas will be reported in 2023 ASH.

AskBio reveals the enrollment of their initial patient into the Phase 1 trial for AB-1005 (AAV2-GDNF), their gene therapy solution to Multiple System Atrophy-Parkinsonian Type (MSA-P).

The analysis of the target COX reveals a competitive landscape with several companies making progress in the development of COX inhibitors.

Medicenna reports promising survival gains from the Phase 2b trial of Bizaxofusp for relapsed Glioblastoma, revealed at the 28th yearly NeuroOncology Society gathering.

On 14 Apr 2023, data from first-in-human study of EXS21546, an A2A receptor antagonist, was reported at the AACR Congress.

EBGLYSS® (lebrikizumab), developed by Almirall, has been given the green light by the European Commission for the treatment of moderate-to-severe atopic dermatitis.

The development of inhibitors around the entire CDK family has become an important branch of drug development in the field of oncology in recent years.